Zetia vs. Praluent
See how Zetia and Praluent compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Zetia is a once-daily oral pill that blocks cholesterol absorption in the gut, while Praluent is an injectable antibody that helps the liver clear more LDL cholesterol from the blood.
Praluent has dedicated trial data showing it reduces heart attacks, strokes, and related hospitalizations in people with existing cardiovascular disease, a benefit not established for Zetia alone.
Generic ezetimibe costs far less out of pocket than Praluent, which has no generic version and requires self-injection every two or four weeks.
Zetia vs. Praluent Drug Summary
Zetia
Zetia (ezetimibe) is a cholesterol absorption inhibitor that lowers LDL cholesterol by blocking its uptake in the small intestine. It's FDA-approved for primary hyperlipidemia, mixed hyperlipidemia, and familial hypercholesterolemia, often paired with a statin. It comes as a 10 mg tablet taken once a day, with or without food.
Praluent
Praluent (alirocumab) is a PCSK9 inhibitor, a lab-made antibody that helps the liver remove more LDL cholesterol from the blood. It's FDA-approved for primary hyperlipidemia, familial hypercholesterolemia, and lowering cardiovascular risk in people with existing heart disease. It's injected under the skin every two or four weeks using a prefilled pen.
Zetia vs. Praluent Side Effects
Zetia
Praluent
Zetia vs. Praluent Dosage
Zetia
Praluent
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg once daily | At the start |
| Maximum dose | 10 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
| STAGE | DOSE | WHEN |
| Starting dose | 75 mg every 2 weeks | At the start |
| Maximum dose | 300 mg every 4 weeks | If needed |
| Dose changes | 2 increases | As tolerated |
Zetia
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg once daily | At the start |
| Maximum dose | 10 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
Praluent
| STAGE | DOSE | WHEN |
| Starting dose | 75 mg every 2 weeks | At the start |
| Maximum dose | 300 mg every 4 weeks | If needed |
| Dose changes | 2 increases | As tolerated |
Zetia vs. Praluent Indications
Zetia
Zetia is used as an add-on to diet, alone or with a statin, to lower LDL cholesterol in adults with high cholesterol. It also treats mixed hyperlipidemia when combined with fenofibrate, and it treats familial hypercholesterolemia in adults and children age 10 and up when combined with a statin.
Primary hyperlipidemia, alone or with a statin
Mixed hyperlipidemia, with fenofibrate
Heterozygous familial hypercholesterolemia, ages 10+, with a statin
Praluent
Praluent is used as an add-on to a maximally tolerated statin to further lower LDL cholesterol in adults with primary hyperlipidemia. It also treats heterozygous familial hypercholesterolemia in patients 8 and older, and it reduces the risk of heart attack, stroke, and related hospitalization in adults with established heart disease.
Primary hyperlipidemia, add-on to statin therapy
Heterozygous familial hypercholesterolemia, ages 8+
Reducing cardiovascular risk in established heart disease
Zetia vs. Praluent Pros and Cons
Zetia
Zetia works through a different pathway than statins, which makes it a useful add-on when a statin alone isn't enough. It's taken as a simple daily pill rather than an injection, and generic versions have made it widely affordable.
Pros
Oral tablet, no injections needed
Generic available, roughly $8 to $50 a month before savings programs
Long track record since its 2002 approval
Can be paired with fenofibrate for mixed hyperlipidemia
Cons
Produces a more modest LDL reduction than PCSK9 inhibitors
Not approved as monotherapy for homozygous familial hypercholesterolemia
Risk of liver enzyme elevation and muscle problems, especially with a statin
Not established to lower cardiovascular events when used alone
Praluent
Praluent offers a distinct mechanism for patients who need more LDL lowering than statins and ezetimibe provide, and it's the only PCSK9 inhibitor with both every-2-week and monthly dosing options. It also has dedicated outcomes data showing cardiovascular risk reduction, though it costs substantially more and has no generic option.
Pros
Flexible dosing: every 2 weeks or once a month
Backed by ODYSSEY OUTCOMES trial for cardiovascular risk reduction
Approved for children with HeFH as young as age 8
Larger average LDL reduction than oral cholesterol drugs
Cons
Requires self-injection with a prefilled pen
Roughly $500 to $640 a month before savings programs, no generic available
Injection site reactions are common
Serious hypersensitivity reactions have been reported
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.